Innovative approaches to optimizing the delivery of vancomycin in individual patients

Advanced Drug Delivery Reviews

Volumn 77, Issue , 2014, Pages 50-57

  Pai, Manjunath P ^a   Neely, Michael ^b,c   Rodvold, Keith A ^d   Lodise, Thomas P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

AUC; Bayesian; Pharmacodynamics; Pharmacokinetics; Trough; Vancomycin

Indexed keywords

BACTERIA; COMPUTER SOFTWARE; CONTROLLED DRUG DELIVERY; PATIENT MONITORING; PHARMACODYNAMICS; PHARMACOKINETICS;

BAYESIAN; CONCENTRATION MONITORING; INDIVIDUAL VARIABILITY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; THERAPEUTIC DRUG MONITORING; TROUGH; VANCOMYCIN;

TARGETED DRUG DELIVERY;

VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; BAYES THEOREM; CALCULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; MATHEMATICAL COMPUTING; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PROCESS OPTIMIZATION; REVIEW; ANIMAL; DRUG EFFECTS; DRUG MONITORING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; DRUG MONITORING; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84919463387     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.016     Document Type: Review

References (71)

1. DeNoon D. Drug-resistant staph may get nastier: experts call for increased efforts to halt MRSA. WebMD Medical News. WebMD Web site. Accessed April 8, 2008. http://www.webmd.com/news/20060831/drug-resistant-staph-may-get-nastier.
2. Kirst H.A., Thompson D.G., Nicas T.I. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. May 1998, 42(5):1303-1304.
3. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. Feb 1 2011, 52(3):285-292.
4. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. Jan 1 2009, 66(1):82-98.
5. Gabrielsson J., Weiner D. Non-compartmental analysis. Methods Mol. Biol. 2012, 929:377-389.
6. Chung J., Oh J.M., Cho E.M., et al. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth. Intensive Care Nov 2011, 39(6):1030-1037.
7. Hermsen E.D., Hanson M., Sankaranarayanan J., Stoner J.A., Florescu M.C., Rupp M.E. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin. Drug Saf. Jan 2010, 9(1):9-14.
8. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. Oct 23 2006, 166(19):2138-2144.
9. Kralovicova K., Spanik S., Halko J., et al. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?. J. Chemother. Dec 1997, 9(6):420-426.
10. Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. Sep 2008, 52(9):3315-3320.
11. Zimmermann A.E., Katona B.G., Plaisance K.I. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy Jan-Feb 1995, 15(1):85-91.
12. van Hal S.J., Paterson D.L., Lodise T.P. Systematic review and meta analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 2013, 57:734-744.
13. Patel N., Pai M.P., Rodvold K.A., Lomaestro B., Drusano G.L., Lodise T.P. Vancomycin: we can't get there from here. Clin. Infect. Dis. 2011, 52(8):969-974.
14. Neely M.N., Youn G., Jones B., et al. Are vancomycin troughs adequate for optimal dosing?. Antimicrob. Agents Chemother. 2014, 58:309-316.
15. Pai M.P., Rodvold K.A. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. Diagn. Microbiol. Infect. Dis. 2014, 78(2):178-187.
16. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 2003, 17(3):479-501.
17. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2004, 2(4):289-300.
18. Moise-Broder P.A., Forrest A., Birmingham M.C., Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 2004, 43(13):925-942.
19. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 2006, 42(Suppl. 1):S35-S39.
20. Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 2011, 52(8):975-981.
21. Clinical Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement (June 2010 Update). CLSI Document M100-S20-U (ISBN 1-56238-729-4) 2010, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
22. Clinical and Laboratory Standards Institute Performance standards for antimicrobial disk susceptibility tests; approved standards, M2-M9 2006, Clinical and Laboratory Standards Institute, Wayne, PA. ninth edition.
23. Mohr J.F., Murray B.E. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2007, 44(12):1536-1542.
24. Drusano G.L., Ambrose P.G., Bhavnani S.M., et al. Vancomycin dose recommendations for hospital-, ventilator- or health care-associated pneumonia and the attainment of vancomycin trough concentrations of 15-20mg/L: cognitive dissonance. 45th Annual Meeting of the Infectious Diseases Society of America, October 4-7, 2007, San Diego, CA 2007.
25. Rodvold K.A., Blum R.A., Fischer J.H., et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob. Agents Chemother. 1988, 32(6):848-852.
26. Bosso J.A., Nappi J., Rudisill C., et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob. Agents Chemother. 2011, 55(12):5475-5479.
27. Cano E.L., Haque N.Z., Welch V.L., et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin. Ther. 2012, 34(1):149-157.
28. Elting L.S., Rubenstein E.B., Kurtin D., et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998, 83(12):2597-2607.
29. Ingram P.R., Lye D.C., Tambyah P.A., Goh W.P., Tam V.H., Fisher D.A. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 2008, 62(1):168-171.
30. Jeffres M.N., Isakow W., Doherty J.A., Micek S.T., Kollef M.H. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 2007, 29(6):1107-1115.
31. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 2008, 52(4):1330-1336.
32. Lodise T.P., Patel N., Lomaestro B.M., Rodvold K.A., Drusano G.L. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 2009, 49(4):507-514.
33. McKamy S., Hernandez E., Jahng M., Moriwaki T., Deveikis A., Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J. Pediatr. 2011, 158(3):422-426.
34. Minejima E., Choi J., Beringer P., Lou M., Tse E., Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob. Agents Chemother. 2011, 55(7):3278-3283.
35. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 2012, 54(6):755-771.
36. Prabaker K.K., Tran T.P., Pratummas T., Goetz M.B., Graber C.J. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J. Hosp. Med. 2012, 7(2):91-97.
37. Spapen H.D., Janssen van Doorn K., Diltoer M., et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann. Intensive Care 2011, 1(1):26.
38. Bergman M.M., Glew R.H., Ebert T.H. Acute interstitial nephritis associated with vancomycin therapy. Arch. Intern. Med. 1988, 148(10):2139-2140.
39. Cimino M.A., Rotstein C., Slaughter R.L., Emrich L.J. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am. J. Med. 1987, 83(6):1091-1097.
40. Cohen E., Dadashev A., Drucker M., Samra Z., Rubinstein E., Garty M. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J. Antimicrob. Chemother. 2002, 49(1):155-160.
41. Colares V.S., Oliveira R.B., Abdulkader R.C. Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol. Dial. Transplant. 2006, (12):3608.
42. Darko W., Medicis J.J., Smith A., Guharoy R., Lehmann D.E. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003, 23(5):643-650.
43. Downs N.J., Neihart R.E., Dolezal J.M., Hodges G.R. Mild nephrotoxicity associated with vancomycin use. Arch. Intern. Med. 1989, 149(8):1777-1781.
44. Fisher B.T., Zaoutis T.E., Leckerman K.H., Localio R., Aplenc R. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr. Blood Cancer 2010, 55(4):655-661.
45. Goetz M.B., Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J. Antimicrob. Chemother. Aug 1993, 32(2):325-334.
46. Hazlewood K.A., Brouse S.D., Pitcher W.D., Hall R.G. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?. Am. J. Med. 2010, 123(2:182):e1-e7.
47. Kullar R., Leonard S.N., Davis S.L., et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011, 31(5):441-448.
48. Marinho D.S., Huf G., Ferreira B.L., et al. The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital. BMC Res. Notes 2011, 4(1):236.
49. Moffett B.S., Kim S., Edwards M. Vancomycin nephrotoxicity may be overstated. J. Pediatr. 2011, 158(5):865-866. (author reply 6).
50. Pritchard L., Baker C., Leggett J., Sehdev P., Brown A., Bayley K.B. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am. J. Med. 2010 Dec, 123(12):1143-1149.
51. Rybak M.J., Albrecht L.M., Boike S.C., Chandrasekar P.H. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 1990, 25(4):679-687.
52. Shen W.C., Chiang Y.C., Chen H.Y., et al. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology 2011, 16(8):697-703.
53. Sorrell T.C., Collignon P.J. A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob. Chemother. 1985, 16(2):235-241.
54. Wong-Beringer A., Joo J., Tse E., Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents 2011, 37(2):95-101.
55. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 2012, 54(5):621-629.
56. Levine D.P. Vancomycin: a history. Clin. Infect. Dis. 2006, 42(Suppl. 1):S5-S12.
57. Moellering R.C. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 2006, 42(Suppl. 1):S3-S4.
58. Suzuki Y., Kawasaki K., Sato Y., et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 2012, 58(4):308-312.
59. Lodise T.P., Patel N., Drusano G. Relationship between vancomycin area under the concentration-time curve (AUC0-24hr) and nephrotoxicity. Platform Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington, DC 2008, Abstract #A-3559.
60. Jelliffe R.W., Schumitzky A., Van Guilder M., et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit. 1993, 15(5):380-393.
61. Bayard D.S., Jelliffe R.W. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J. Pharmacokinet. Pharmacodyn. 2004, 31(1):75-107.
62. Jelliffe R.W., Schumitzky A. Modeling, adaptive control, and optimal drug therapy. Med. Prog. Technol. 1990, 16(1-2):95-110.
63. Aubron C., Corallo C.E., Nunn M.O., Dooley M.J., Cheng A.C. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann. Pharmacother. 2011, 45(10):1193-1198.
64. Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin. Pharmacokinet. 2013, 52(1):9-22.
65. Pai M.P., Russo A., Novelli A., Venditti M., Falcone M. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob. Agents. Chemother. 2014, 58(6):3162-3167.
66. Begg E.J., Barclay M.L., Duffull S.B. A suggested approach to once-daily aminoglycoside dosing. Br. J. Clin. Pharmacol. 1995, 39(6):605-609.
67. Sawchuk R.J., Zaske D.E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 1976, 4(2):183-195.
68. Holmes N.E., Turnidge J.D., Munckhof W.J., et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2013, 57(4):1654-1663.
69. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
70. Lodise T.P., Drusano G.L., Zasowski E., et al. Vancomycin exposure in patients with MRSA bloodstream infections: how much is enough?. Clin. Infect. Dis. 2014, 59(5):666-675.
71. Wong C., Kumar S.S., Graham G.G., et al. Comparing dose prediction software used to manage gentamicin dosing. Intern. Med. J. 2013, 43(5):519-525.